Global Life Science Business Partnering (GLSBP)

Private equity giant Advent International will acquire a 50.1% stake in Suven Pharmaceuticals from Jasti family for nearly INR 6,300 crores (~US$800Million).
JB Pharma to buy Glenmark’s cardiac brand for IN? 314 crores (~US$40 Million).
Cipla invests €15 Million in Ethris for developing mRNA-based therapies.
Neurological healthcare start-up In-Med Prognostics raises $2.13 Million in funding led by Exxora.
Boehringer partners with Torrent Pharma to co-market diabetes drugs in India.
Tandem inks $216 Million deal for AMF Medical and its insulin patch pump.
Eli Lilly partners with generics maker Eva to boost insulin access in Africa.
Merck & Co. inks pact with Indonesia's Bio Farma to make HPV vaccine.
Crown Bioscience inks deal with ERS Genomics for gene editing tech.
Praxis Precision enters epilepsy research deal with UCB.
Kite and Arcellx ink multiple myeloma collaboration.
Nykode enters partnership with Richter-Helm BioLogics

Updates at Aagami:

Aagami to attend Biotech Showcase 2023 in San Francisco (January 9–11). Meeting calendar is filling fast with only few slots open. If you would like to meet, please send your request soon.
Aagami CEO Dinesh Jain and VP Godwyn Francis completed a very fruitful business trip to Republic of Korea in December 2022. Aagami was a part of the State of Illinois Trade Delegation to Seoul, Korea.
Aagami celebrating 20 years in business. As a part of its 20^th Anniversary year, Aagami will offer special offers and benefits to its clients (Valid until 31^st March 2023).
Aagami received new assignment from an existing client; also, were awarded contract extension by 2 clients.
In December 2022, Aagami also won a new client from Canada.

INFOCUS: Select opportunities available at Aagami:

For Partnering/Licensing/ Investment:

Licensing/Co-development: Easy to apply world’s First Transdermal Tizanidine Patch for the Management of Spasticity. Impressive Phase 1 results. Ready to initiate Phase 2.
Midwest US based Pharma’s First-in-Class Non-Opioid Analgesic for both chronic and acute Pain Relief – Seeking funding/licensing/co-development partnerships.
A single (monovalent) vaccine for Targeting Salmonella, ETEC / E. coli, Campylobacter, Shigella. An unmet need for treating Bacterial Dysentery. Seeking funding/licensing/co-development partnerships.

For Acquisition:

Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.